We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Exploring Innovations in SPR & Combination Screening

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Scientists from AstraZeneca, Chugai Pharmaceutical, Sanford-Burnham Medical Research Institute, and UT Southwestern Medical Center will be among Genedata customers discussing innovations in high content imaging, high throughput screening, compound combination screening, and other related topics    

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the Genedata Screener® Global User Group Meetings will be held in Asia, Europe, and North America during September 2014. Screening experts from global pharmaceutical companies and leading research organizations will gather for annual User Group Meetings to share best practices, case studies, and upcoming challenges in all areas of screening. This year's sessions will also showcase enhancements and new functionality in the recently released Genedata Screener version 12, which includes data analysis capabilities for Surface Plasmon Resonance (SPR), Thermal Shift, as well as Combination and Panel Screens.
 
Most of the world's leading pharmaceutical companies, academic institutions, and contract research organizations rely on Genedata Screener as their single computational platform for all plate-based screening. Genedata Screener users from AstraZeneca, Chugai Pharmaceuticals, Sanford-Burnham Institute, and University of Texas Southwestern Medical Center will be among the speakers presenting their research work using Genedata Screener. Featured sessions will explore topics such as:  
 
•    application of high content imaging and stem cells within phenotypic drug discovery;
•    identification of novel natural products and synthetic molecules for treatment of lung cancer; and
•    best practices for applying Genedata Screener in a variety of screening environments.
 
"Screener User Group Meetings bring together many of the world's thought leaders in the application of screening technologies in pharmaceutical R&D," said Dr. Othmar Pfannes, CEO of Genedata. "We are proud to host these annual events, which provide forums in which scientists can share their experiences in advancing scientific progress with Genedata Screener -- the most comprehensive computational platform for screening worldwide."
 
Genedata Screener User Group Meetings are held regionally throughout the world so that customers can easily access and participate in these knowledge-sharing events. Meetings for 2014 will be held in: Tokyo, Japan (Sept. 4); Basel, Switzerland (Sept. 9-10); Boston, MA (Sept.16); and San Francisco, CA (Sept. 18).